Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6635618 | CUMBERLAND PHARMS | Glycopeptide phosphonate derivatives |
Sep, 2023
(3 months from now) | |
US7531623 | CUMBERLAND PHARMS | Hydrochloride salts of a glycopeptide phosphonate derivative |
Jan, 2027
(3 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6858584 | CUMBERLAND PHARMS | Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin |
Aug, 2022
(9 months ago) |
Market Authorisation Date: 11 September, 2009
Treatment: Method for treating bacterial infection
Dosage: POWDER;INTRAVENOUS
46
United States
9
Australia
8
Japan
7
Canada
6
Spain
6
European Union
5
Germany
5
Slovenia
4
Austria
4
China
4
Korea, Republic of
3
Hong Kong
3
Denmark
3
Poland
3
Brazil
3
Norway
3
Portugal
3
Hungary
2
Cyprus
2
Taiwan
2
Mexico
1
Malaysia
1
Iceland
1
Czech Republic
1
Yugoslavia
1
Ukraine
1
Argentina
1
EA
1
New Zealand
1
Croatia
1
Israel
1
South Africa
1
Slovakia
1
Egypt
1
Luxembourg
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic